Welcome

Welcome to the Carolina BioOncology Institute (CBI).  We are a cancer therapy and research institute.  Our staff are dedicated to advancing the field of cancer research by making available the latest developments in therapeutic options.  CBI has developed an early phase clinical trial program which represents the cutting edge in immunotherapy and personalized cancer options.  Additionally, CBI is the incubator for BioCytics, a research and development firm working to identify novel drug targets.  We are excited that you are considering a visit to our clinic and we look forward to providing you with the  most recent clinical trial options and the highest quality care.

 

 

Recent Clincial Trials

Protocol INCB 39110-106: A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Sponsor: Incyte Corporation
Status: Enrolling
More Details

Protocol CP-MGD009-01: A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3

Sponsor: MacroGenics, Inc.
Status: enrolling
More Details

Protocol D6060C00001: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects with Selected Advanced Solid Tumors

Sponsor: MedImmune, LLC, a wholly owned subsidiary of Astra Zeneca PLC
Status: enrolling
More Details

Protocol D4190C00006: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer

Sponsor: MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC
Status: enrolling
More Details

Protocol INCB24360-203 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors

Sponsor: InCyte Corporation
Status: Recruiting participants
More Details

Protocol D4191C00011 (AZ11) A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) with a Sequential Switch to a 2nd IMT (MEDI4736) in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV)

Sponsor: AstraZeneca
Status: Closed to new participants.
More Details

Protocol MGA271: A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3

Sponsor: MacroGenics, Inc.
Status: Recruiting participants
More Details

Protocol CP-MGD007-01: A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma.

Sponsor: Macrogenics, Inc.
Status: Recruiting participants
More Details

Protocol CD-ON-MEDI4736-1108: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 (anti-PD-L1) in Subjects with Advanced Solid Tumors

Sponsor: MedImmune, a wholly-owned subsidiary of Astra Zeneca
Status: Recruiting participants
More Details

Protocol D4981C00001: A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 (OX40 agonist) in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

Sponsor: MedImmune, a wholly-owned subsidiary of Astra Zeneca
Status: Recruitment Closed
More Details

Protocol D4191C00003: A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736 (anti-PD-L1) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen

Sponsor: Astra Zeneca
Status: Recruiting participants
More Details

Protocol EMR 100070-001: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of an anti-PD-L1 antibody in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Sponsor: Merck
Status: Recruiting participants
More Details

Protocol GO28754: A Phase II, Multicenter, Single-Arm Study of MPDL3280A (anti-PD-L1) in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Roche-Genentech
Status: Recruiting participants
More Details

Protocol GP28328: A Phase IB Study of the Safety and Pharmacology of MPDL3280A (anti-PD-L1) Administered with Bevacizumab and/or Chemotherapy in Patients with Advanced Solid Tumors

Sponsor: Genentech
Status: Recruiting participants
More Details

Protocol PCD4989g: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A (anti-PD-L1) Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors of Hematologic Malignancies

Sponsor: Genentech
Status: Recruiting participants
More Details

Latest News

Setting Off a Smart Bomb

November 23rd, 2015

          When Kevin Day was diagnosed with advanced renal cell carcinoma in the fall of 2011 at the age of 50, he was told he had just two years to live. His left kidney was removed, and he was put on Sutent (sunitinib) — the targeted drug that is a standard […]

READ MORE

Celebrating 10 Years in Patient Care and Research

October 15th, 2015

We are excited to be celebrating our 10th year in business!  We saw our first patient September, 2005, and here we are ten years later continuing to treat patients and conduct clinical research trials having made great strides over the years.  Thank you to everyone for your support and we look forward to serving our […]

READ MORE

pad-pdf

9801 Kincey Ave,
Suite 145 Bostick Building
Huntersville, NC 28078
Ph:   704.947.6599
Fax:  704.947.6597

Get Directions

Social Updates